Capmatinib (Figure 1), a TKI, was approved by the U.S. Food and Drug Administration (FDA) in 2020 to treat metastatic NSCLC patients with MET exon 14 skipping mutation [4]. This evidence concerns the gene MET and non-small cell lung carcinoma.